martes, 6 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 6, 2026

$10,000 in FNGU Became $8,392 in One Session as Tech Leverage Cut Both Ways

View original at finance.yahoo.com
$10,000 in FNGU Became $8,392 in One Session as Tech Leverage Cut Both Ways Quick Read FNGU shed 16% in a single session on June 5, turning a $10,000 position into roughly $8,400, yet still holds a 28% one-year return…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Broadcom AI semiconductor revenue compounded from $5.20 billion to $8.40 billion to $10.80 billion across the three quarters preceding Q3 FY26 guidance.

    60% confidence

  • Broadcom guided Q3 FY26 total revenue to approximately $29.4 billion.

    60% confidence

  • Broadcom guided Q3 FY26 AI semiconductor revenue to $16.0 billion, representing more than 200% year-over-year growth.

    60% confidence

  • Despite the June selloff, FNGU remains up 28.1% over twelve months and up 6.85% year to date.

    60% confidence

  • Broadcom Q2 FY26 non-GAAP EPS was $2.44, beating the Wall Street consensus of $2.3972.

    60% confidence

  • NVIDIA's 6% decline on June 5 equated to approximately $279 billion in single-session market capitalization loss.

    60% confidence

  • Broadcom Q2 FY26 total revenue was $22.19 billion.

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
$10,000 in FNGU Became $8,392 in One Session as Tech Leverage Cut Both Ways — Source | Via News | es.VIA.NEWS